You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. BlueBox: A Complete Code Blue Data Recorder, Phase II

    SBC: NeoVative, Inc.            Topic: 400

    “Code blue” is the signal used in hospitals to call for an immediate cardiopulmonary resuscitation (CPR) following a cardiac or respiratory arrest. Reviewing the performance of the “code blue team” is a cornerstone for improving outcomes. The current standard of using handwritten records on a paper “code sheet” does not allow measurement of key quality indicators and is subject to huma ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    Abstract. LEXEO Therapeutics, LLC, is an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stress. LEX01, the 1st LEXEO product, is a 1st in class, next generation gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency, an autosomal recessive hereditary disorder associated with low serum levels of AAT. AAT (SERPINA1), a ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Idiopathic pulmonary fibrosis (IPF), the most common of the interstitial lung diseases, occurs in about 128,000 people, with 48,000 new cases diagnosed annually in the US. The typical clinical course is a progressive fibrotic disease characterized by scarring and `honeycombingandapos; of the lungs causing an irreversible loss of the tissueandapos;s ability to transport oxygen. Co-morbid pulmonary ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. MISSION U: A MULTIMEDIA TRAINING TOOL FOR TREATING INDIVIDUALS WITH CO-OCCURRING MENTAL HEALTH AND SUBSTANCE USE DISORDERS

    SBC: PRAXIS, INC.            Topic: 350

    Co-occurring mental health and substance use disorders (COD) are common in the United States and providers have been challenged to provide effective treatments. As a consequence, their clients with COD may experience poor treatment engagement, symptom exacerbation and cycle in and out of emergency services. This is particularly true for underrepresented populations with a COD including individuals ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Online Training For Addressing Perinatal Depression

    SBC: PRAXIS, INC.            Topic: 104

    Project Summary The primary goal of this proposal is to develop, implement, and evaluate an online module to improve obstetric providers’ knowledge, attitudes, and practices regarding perinatal mood and anxiety disorders. Upwards of 1 in 5 women suffer from perinatal mood and anxiety disorders. Left untreated, they have deleterious effects on maternal and birth outcomes, infant attachment, and c ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users

    SBC: AUTOMATE SCIENTIFIC, INC.            Topic: NIDA

    Abstract E cigarettes (E-cigs) are increasingly popular worldwide, in particular, among youths. E-cigs may contribute to nicotine addiction and are unlikely to discourage conventional cigarette smoking. Mainstream and second-hand E-cig aerosols contain, in addition to nicotine, detectable levels of toxins including carcinogens and heavy metals such as formaldehyde, benzene, nitrosamines, cadmium a ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A Mobile Tai Chi Platform for Fall Prevention in Older Adults

    SBC: BIOSENSICS LLC            Topic: NIA

    Project Summary Exercise-based interventions have been recently shown to have great potential for preserving and restoring cognitive function in older adults. In this context, Tai Chi has gained the interest of researchers and clinicians because it incorporates physical, cognitive, social, and meditative components within the same activity. Such multimodal exercise modality is expected to have a p ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury

    SBC: Mitovation, Inc.            Topic: 101

    Neonatal hypoxia/ischemia is a known cause of cerebral damage resulting from inadequate blood flow and/or oxygen delivery to the infant brain before, during, or after birth. The occurrence among hospital deliveries is ~2-4 per 1000 full-term births with a drastic increase among premature newborns. The deficit in oxygen delivery to the brain results in extensive damage and severe disabilities. Rest ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Optical photothermal IR (O-PTIR) microscopy for chemical imaging of living cells at sub-micron resolution

    SBC: PHOTOTHERMAL SPECTROSCOPY CORP.            Topic: 102

    Optical photothermal IR (OPTIR) microscopy for chemical imaging of living cells at sub-micron resolution Project Summary/Abstract Photothermal Spectroscopy Corp (PSC) and Prof. Ji-Xin Cheng of Boston University in collaboration with Prof. Rohith Reddy (University of Houston) propose to develop, validate, and commercialize a novel technical called Optical Photothermal Infrared (OPTIR) spectroscopy. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government